Advances in Antithrombotic Agents

Author(s): Ranjan Chakrabarti, Saibal Kumar Das

Journal Name: Cardiovascular & Hematological Agents in Medicinal Chemistry
(Formerly Current Medicinal Chemistry - Cardiovascular & Hematological Agents)

Volume 5 , Issue 3 , 2007

Become EABM
Become Reviewer

Abstract:

Thrombosis is the condition where an imbalance in the homeostatic mechanism results in unwanted intravascular thrombus formation. Imbalances in this highly regulated process of coagulation and anticoagulation can lead to a variety of pathophysiological conditions leading to stroke, pulmonary heart attack and other serious conditions. In the western world, thromboembolic diseases are the leading cause of morbidity and mortality. Remarkable progress has occurred over the last decade in the development of antithrombotic drugs, which can be classified into 3 major categories – Anticoagulants, Antiplatelets and thrombolytics. Increased understanding of the pathobiology of thrombotic and vascular disorders has helped researchers to target novel pathways involving the coagulation, thrombolytic, fibrinolytic and integrin systems. Traditionally aspirin and unfractionated heparin was used for myocardial infarction. Newer antiplatelet agents such as, clopidogrel, GP IIb/IIIa inhibitors, low molecular weight heparin, direct thrombin inhibitors and several improved thrombolytic agents have been introduced for clinical use. This review will discuss different important drugs, which have been launched in recent years and also some new targets pursued by different companies.

Keywords: deep vein thrombosis, Anticoagulants, Warfarin, Fondaparinux Sodium, Antiplatelet therapies, Direct Factor Xa Inhibitors

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 5
ISSUE: 3
Year: 2007
Page: [175 - 185]
Pages: 11
DOI: 10.2174/187152507781058717
Price: $65

Article Metrics

PDF: 5